Tarlatamab
20200040
Phase 1 small_molecule completed
Quick answer
Tarlatamab for Neuroendocrine Prostate Cancer is a Phase 1 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen
- Indication
- Neuroendocrine Prostate Cancer
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed